Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Univariate analysis revealed that the presence of diabetes mellitus, history of fragility fracture, glucocorticoid use for ≥ 6 months, femoral neck BMD T-score, serum PINP, serum β-CTX, serum 25(OH)D, and serum OC were associated with poor treatment response (P < 0.05) (Table 2).
Source: Univariate analysis of osteoporosis treatment efficacy. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cohort study.
Cohort study
Examines exposures and outcomes over time within a defined group.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Participants were randomly allocated to a training set (n = 380) and a validation set (n = 163) in a 7:3 ratio.
Source: Abstract.
This single-center retrospective cohort study consecutively enrolled patients diagnosed with primary osteoporosis who initiated standard anti-osteoporosis treatment at osteoporosis specialty clinic or orthopedics inpatient department of the Third Affiliated Hospital, Guangzhou Medical University, and the Fifth Affiliated Hospital, Guangzhou Medical University between January 2021 and December 2024.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Predicting poor response to anti-osteoporosis therapy: a machine learning model integrating clinical and novel biomarker data
Cohort study · Frontiers in Medicine · 2026
Original publication title
Predicting poor response to anti-osteoporosis therapy: a machine learning model integrating clinical and novel biomarker data
Copyright © 2026 Bi, Zhang, Zhang and Li.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
This study was conducted to develop and validate a prediction model integrating clinical characteristics and novel biomarkers. The goal was to identify patients at high risk for a poor response to standard anti-osteoporosis therapy prior to treatment initiation, thereby supporting personalized therapeutic decision-making.
Source: ObjectiveAbstract: What methods does the paper describe?
A retrospective analysis was performed on 543 patients with primary osteoporosis admitted between January 2021 and December 2024. All patients received 12 months of standard treatment. Participants were randomly allocated to a training set (n = 380) and a validation set (n = 163) in a 7:3 ratio. In the training set, univariate analysis, Least Absolute Shrinkage and Selection Operator (LASSO) regression, and multivariate logistic regression were used to determine independent predictors. Three machine learning models: Random Forest (RF), Support Vector Machine (SVM), and K-Nearest Neighbors (KNN): were then constructed.
Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), calibration curves, and decision curve analysis (DCA). SHapley Additive exPlanations (SHAP) values were used to interpret the optimal model.
Source: MethodsAbstract: Results
Baseline characteristics were comparable between the training and validation sets (P > 0.05). Eight independent predictors of poor treatment response were identified: comorbid diabetes, history of fragility fracture, glucocorticoid use for ≥ 6 months, femoral neck bone mineral density T-score, and serum levels of osteocalcin, procollagen type I N-terminal propeptide, β-CrossLaps of type I collagen (β-CTX), and 25-Hydroxyvitamin D. Among the models, the RF algorithm demonstrated superior performance, with an AUC of 0.856 (95% CI: 0.808 to 0.905) in the training set and 0.825 (95% CI: 0.718 to 0.933) in the validation set.
The model was well-calibrated, and DCA indicated a high net benefit. SHAP analysis confirmed serum β-CTX as the most significant predictive variable.
Source: ResultsAbstract: Conclusion
A predictive model integrating multi-dimensional factors was successfully developed and validated for assessing osteoporosis treatment efficacy. The RF-based model exhibited robust predictive performance and clinical utility. It shows potential for pre-therapeutic identification of high-risk patients, facilitating precision management in osteoporosis.
Source: ConclusionAuthors’ abstract
Objective
This study was conducted to develop and validate a prediction model integrating clinical characteristics and novel biomarkers. The goal was to identify patients at high risk for a poor response to standard anti-osteoporosis therapy prior to treatment initiation, thereby supporting personalized therapeutic decision-making.
Methods
A retrospective analysis was performed on 543 patients with primary osteoporosis admitted between January 2021 and December 2024. All patients received 12 months of standard treatment. Participants were randomly allocated to a training set (n = 380) and a validation set (n = 163) in a 7:3 ratio. In the training set, univariate analysis, Least Absolute Shrinkage and Selection Operator (LASSO) regression, and multivariate logistic regression were used to determine independent predictors. Three machine learning models: Random Forest (RF), Support Vector Machine (SVM), and K-Nearest Neighbors (KNN): were then constructed.
Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), calibration curves, and decision curve analysis (DCA). SHapley Additive exPlanations (SHAP) values were used to interpret the optimal model.
Results
Baseline characteristics were comparable between the training and validation sets (P > 0.05). Eight independent predictors of poor treatment response were identified: comorbid diabetes, history of fragility fracture, glucocorticoid use for ≥ 6 months, femoral neck bone mineral density T-score, and serum levels of osteocalcin, procollagen type I N-terminal propeptide, β-CrossLaps of type I collagen (β-CTX), and 25-Hydroxyvitamin D. Among the models, the RF algorithm demonstrated superior performance, with an AUC of 0.856 (95% CI: 0.808 to 0.905) in the training set and 0.825 (95% CI: 0.718 to 0.933) in the validation set.
The model was well-calibrated, and DCA indicated a high net benefit. SHAP analysis confirmed serum β-CTX as the most significant predictive variable.
Conclusion
A predictive model integrating multi-dimensional factors was successfully developed and validated for assessing osteoporosis treatment efficacy. The RF-based model exhibited robust predictive performance and clinical utility. It shows potential for pre-therapeutic identification of high-risk patients, facilitating precision management in osteoporosis.
Publication and source details
Original title: Predicting poor response to anti-osteoporosis therapy: a machine learning model integrating clinical and novel biomarker data
Yannan Bi; Maolin Zhang; Weiqiong Zhang; Jiahong Li
Frontiers in Medicine · 2026
* Correspondence: Maolin Zhang, gysy1220@163.comCopyright © 2026 Bi, Zhang, Zhang and Li.2026Bi, Zhang, Zhang and Lihttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.The author(s) declared that financial support was not received for this work and/or its publication.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-10T22:32:03.213156+00:00
DOI: 10.3389/fmed.2026.1786209 · PMC13216482